EGFR and ovarian cancer: Among the class III Sirts, Sirt1 is upregulated in chemoresistant EOC [157]; acquired cisplatin resistance associates with alterations in the expression of BRCA1, SIRT1 and EGFR in ovarian cancer cells [158]; SIRT3 and SIRT6 are downregulated in ovarian carcinoma [159,160]; and SIRT4 overexpression in ovarian cancer cells modulates invasiveness [161,162].